{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T02:32:29Z","timestamp":1791253949672,"version":"4.1.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100012899","name":"Lanzhou University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012899","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004775","name":"Gansu Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["23JRRA1050"],"award-info":[{"award-number":["23JRRA1050"]}],"id":[{"id":"10.13039\/501100004775","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.bcp.2025.117111","type":"journal-article","created":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T12:49:56Z","timestamp":1751633396000},"page":"117111","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["A novel 3-alkenylindol-2-one derivative selectively inhibits the growth of acute myeloid leukemia via modulation of the MYC-PRMT pathway"],"prefix":"10.1016","volume":"240","author":[{"given":"Shuhong","family":"Dong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiying","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingwen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingqi","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiwu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baolai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.bcp.2025.117111_b0005","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/s41580-019-0155-x","article-title":"The regulation, functions and clinical relevance of arginine methylation","volume":"20","author":"Guccione","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.bcp.2025.117111_b0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116048","article-title":"Protein arginine methyltransferases (PRMTs): orchestrators of cancer pathogenesis, immunotherapy dynamics, and drug resistance","volume":"221","author":"Gao","year":"2024","journal-title":"Biochem. Pharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2025.117111_b0015","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.molcel.2016.11.003","article-title":"Arginine methylation: the coming of age","volume":"65","author":"Blanc","year":"2017","journal-title":"Mol. Cell"},{"issue":"7","key":"10.1016\/j.bcp.2025.117111_b0020","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/s41573-021-00159-8","article-title":"Protein arginine methylation: from enigmatic functions to therapeutic targeting","volume":"20","author":"Wu","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bcp.2025.117111_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2021.115829","article-title":"Ribavirin inhibits the growth and ascites formation of hepatocellular carcinoma through downregulation of type I CARM1 and type II PRMT5","volume":"435","author":"Tian","year":"2022","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"5","key":"10.1016\/j.bcp.2025.117111_b0030","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/s11010-022-04577-z","article-title":"Downregulation of PRMT5 by AMI-1 enhances therapeutic efficacy of compound kushen injection in lung carcinoma in vitro and in vivo","volume":"478","author":"Yang","year":"2023","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.bcp.2025.117111_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2022.110305","article-title":"Metabolomics study of ribavirin in the treatment of orthotopic lung cancer based on UPLC-Q-TOF\/MS","volume":"370","author":"Zhu","year":"2023","journal-title":"Chem. Biol. Interact."},{"issue":"1","key":"10.1016\/j.bcp.2025.117111_b0040","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/bcpt.13736","article-title":"Ribavirin inhibits cell proliferation and metastasis and prolongs survival in soft tissue sarcomas by downregulating both protein arginine methyltransferases 1 and 5","volume":"131","author":"Zhang","year":"2022","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"issue":"21","key":"10.1016\/j.bcp.2025.117111_b0045","doi-asserted-by":"crossref","first-page":"4357","DOI":"10.1016\/j.molcel.2021.09.011","article-title":"Cellular pathways influenced by protein arginine methylation: Implications for cancer","volume":"81","author":"Xu","year":"2021","journal-title":"Mol. Cell"},{"issue":"4","key":"10.1016\/j.bcp.2025.117111_b0050","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/s41419-023-05752-w","article-title":"PRMT1 reverts the immune escape of necroptotic colon cancer through RIP3 methylation","volume":"14","author":"Zhang","year":"2023","journal-title":"Cell Death Dis."},{"issue":"7","key":"10.1016\/j.bcp.2025.117111_b0055","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1158\/0008-5472.CAN-23-2266","article-title":"PRMT1 sustains de Novo fatty acid synthesis by methylating PHGDH to drive chemoresistance in triple-negative breast cancer","volume":"84","author":"Yamamoto","year":"2024","journal-title":"Cancer Res."},{"issue":"22","key":"10.1016\/j.bcp.2025.117111_b0060","doi-asserted-by":"crossref","first-page":"4904","DOI":"10.1158\/0008-5472.CAN-20-1228","article-title":"Protein arginine methyltransferase 5 promotes pICln-dependent androgen receptor transcription in castration-resistant prostate cancer","volume":"80","author":"Beketova","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2025.117111_b0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107354","article-title":"Methylation modification of non-histone proteins in breast cancer: an emerging targeted therapeutic strategy","volume":"208","author":"Huang","year":"2024","journal-title":"Pharmacol. Res."},{"issue":"6","key":"10.1016\/j.bcp.2025.117111_b0070","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1182\/blood.2019001282","article-title":"PRMT1-mediated FLT3 arginine methylation promotes maintenance of FLT3-ITD(+) acute myeloid leukemia","volume":"134","author":"He","year":"2019","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.bcp.2025.117111_b0075","doi-asserted-by":"crossref","first-page":"8888","DOI":"10.1021\/acs.jmedchem.7b01134","article-title":"Development of potent type I protein arginine methyltransferase (PRMT) inhibitors of leukemia cell proliferation","volume":"60","author":"Wang","year":"2017","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.bcp.2025.117111_b0080","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/leu.2015.308","article-title":"The dual epigenetic role of PRMT5 in acute myeloid leukemia: gene activation and repression via histone arginine methylation","volume":"30","author":"Tarighat","year":"2016","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.bcp.2025.117111_b0085","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.cmet.2022.04.004","article-title":"Loss of PRMT7 reprograms glycine metabolism to selectively eradicate leukemia stem cells in CML","volume":"34","author":"Liu","year":"2022","journal-title":"Cell Metab."},{"issue":"8","key":"10.1016\/j.bcp.2025.117111_b0090","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1002\/mc.23550","article-title":"PRMT1 inhibition promotes ferroptosis sensitivity via ACSL1 upregulation in acute myeloid leukemia","volume":"62","author":"Zhou","year":"2023","journal-title":"Mol. Carcinog."},{"issue":"1","key":"10.1016\/j.bcp.2025.117111_b0095","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ccell.2019.05.014","article-title":"Anti-tumor activity of the Type I PRMT inhibitor, GSK3368715, synergizes with PRMT5 inhibition through MTAP loss","volume":"36","author":"Fedoriw","year":"2019","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.bcp.2025.117111_b0100","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ccell.2019.06.004","article-title":"Targeting PRMT1 and PRMT5 family members to push cancer cells over the edge","volume":"36","author":"Srour","year":"2019","journal-title":"Cancer Cell"},{"issue":"11","key":"10.1016\/j.bcp.2025.117111_b0105","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.molmed.2019.05.007","article-title":"PRMTs and arginine methylation: cancer's best-kept secret?","volume":"25","author":"Jarrold","year":"2019","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.bcp.2025.117111_b0110","doi-asserted-by":"crossref","DOI":"10.1177\/20406207241275376","article-title":"Phase I\/II study of the clinical activity and safety of GSK3326595 in patients with myeloid neoplasms","volume":"15","author":"Watts","year":"2024","journal-title":"Ther. Adv. Hematol."},{"issue":"3","key":"10.1016\/j.bcp.2025.117111_b0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2025.108201","article-title":"Biomedical effects of protein arginine methyltransferase inhibitors","volume":"301","author":"Cao","year":"2025","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2025.117111_b0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112780","article-title":"Design, synthesis and biological evaluation of indole-2-one derivatives as potent BRD4 inhibitors","volume":"208","author":"Xu","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bcp.2025.117111_b0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2021.115450","article-title":"Ribavirin inhibits colorectal cancer growth by downregulating PRMT5 expression and H3R8me2s and H4R3me2s accumulation","volume":"415","author":"Ge","year":"2021","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"2","key":"10.1016\/j.bcp.2025.117111_b0130","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1158\/1078-0432.CCR-20-1346","article-title":"BET inhibition enhances the antileukemic activity of low-dose venetoclax in acute myeloid leukemia","volume":"27","author":"Ramsey","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.bcp.2025.117111_b0135","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.bcp.2025.117111_b0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2021.101244","article-title":"FLT3 inhibition by olverembatinib (HQP1351) downregulates MCL-1 and synergizes with BCL-2 inhibitor lisaftoclax (APG-2575) in preclinical models of FLT3-ITD mutant acute myeloid leukemia","volume":"15","author":"Fang","year":"2022","journal-title":"Transl. Oncol."},{"issue":"4","key":"10.1016\/j.bcp.2025.117111_b0145","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s11912-024-01503-y","article-title":"Novel therapeutic targets in acute myeloid leukemia (AML)","volume":"26","author":"Wysota","year":"2024","journal-title":"Curr. Oncol. Rep."},{"issue":"5","key":"10.1016\/j.bcp.2025.117111_b0150","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.tips.2024.03.005","article-title":"AML treatment: conventional chemotherapy and emerging novel agents","volume":"45","author":"Forsberg","year":"2024","journal-title":"Trends Pharmacol. Sci."},{"issue":"1","key":"10.1016\/j.bcp.2025.117111_b0155","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41571-021-00549-2","article-title":"The MYC oncogene - the grand orchestrator of cancer growth and immune evasion","volume":"19","author":"Dhanasekaran","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.bcp.2025.117111_b0160","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1002\/hep.31864","article-title":"Myelocytomatosis-protein arginine N-methyltransferase 5 axis defines the tumorigenesis and immune response in hepatocellular carcinoma","volume":"74","author":"Luo","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.bcp.2025.117111_b0165","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.semcancer.2020.11.008","article-title":"Epigenetic modifications of c-MYC: Role in cancer cell reprogramming, progression and chemoresistance","volume":"83","author":"Fatma","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.bcp.2025.117111_b0170","article-title":"Protein arginine methylation: an emerging modification in cancer immunity and immunotherapy","volume":"13","author":"Dai","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2025.117111_b0175","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.2147\/JIR.S364190","article-title":"The influence of arginine methylation in immunity and inflammation","volume":"15","author":"Srour","year":"2022","journal-title":"J. Inflamm. Res."},{"key":"10.1016\/j.bcp.2025.117111_b0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107205","article-title":"Epigenetic modulations in triple-negative breast cancer: Therapeutic implications for tumor microenvironment","volume":"204","author":"Zhou","year":"2024","journal-title":"Pharmacol. Res."},{"issue":"10","key":"10.1016\/j.bcp.2025.117111_b0185","doi-asserted-by":"crossref","first-page":"4437","DOI":"10.7150\/thno.42047","article-title":"PRMT5-dependent transcriptional repression of c-Myc target genes promotes gastric cancer progression","volume":"10","author":"Liu","year":"2020","journal-title":"Theranostics"},{"issue":"8","key":"10.1016\/j.bcp.2025.117111_b0190","doi-asserted-by":"crossref","first-page":"199","DOI":"10.15698\/cst2020.08.228","article-title":"PRMT5 function and targeting in cancer","volume":"4","author":"Kim","year":"2020","journal-title":"Cell Stress"},{"issue":"7569","key":"10.1016\/j.bcp.2025.117111_b0195","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/nature14985","article-title":"The spliceosome is a therapeutic vulnerability in MYC-driven cancer","volume":"525","author":"Hsu","year":"2015","journal-title":"Nature"},{"issue":"17","key":"10.1016\/j.bcp.2025.117111_b0200","doi-asserted-by":"crossref","first-page":"4613","DOI":"10.1158\/0008-5472.CAN-17-0216","article-title":"PRMT1-mediated translation regulation is a crucial vulnerability of cancer","volume":"77","author":"Hsu","year":"2017","journal-title":"Cancer Res."},{"issue":"8","key":"10.1016\/j.bcp.2025.117111_b0205","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1158\/1078-0432.CCR-18-3200","article-title":"Biological consequences of MHC-II expression by tumor cells in cancer","volume":"25","author":"Axelrod","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"551","key":"10.1016\/j.bcp.2025.117111_b0210","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaz5683","article-title":"PRMT5 control of cGAS\/STING and NLRC5 pathways defines melanoma response to antitumor immunity","volume":"12","author":"Kim","year":"2020","journal-title":"Sci. Transl. Med."},{"issue":"24","key":"10.1016\/j.bcp.2025.117111_b0215","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1056\/NEJMoa1808777","article-title":"Immune escape of relapsed AML cells after allogeneic transplantation","volume":"379","author":"Christopher","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.bcp.2025.117111_b0220","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s12943-023-01889-6","article-title":"Relapse of acute myeloid leukemia after allogeneic stem cell transplantation: immune escape mechanisms and current implications for therapy","volume":"22","author":"Sauerer","year":"2023","journal-title":"Mol. Cancer"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295225003764?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295225003764?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T21:06:37Z","timestamp":1755810397000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295225003764"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":44,"alternative-id":["S0006295225003764"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2025.117111","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A novel 3-alkenylindol-2-one derivative selectively inhibits the growth of acute myeloid leukemia via modulation of the MYC-PRMT pathway","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2025.117111","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117111"}}